drugset / Trial / NCT05613088
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2024-06-17
- Completion
- 2025-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Farletuzumab Ecteribulin | Unknown | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Topotecan | Small molecule | — | — |